Are serial measurements of CA 19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

British Journal of Cancer

Volumn 77, Issue 2, 1998, Pages 325-328

  Gogas, H ^a   Lofts, F J ^a   Evans, T R J ^a   Daryanani, S ^a   Mansi, J L ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

CA19 9; Cancer chemotherapy; Pancreas; Response

Indexed keywords

ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CISPLATIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; ADENOCARCINOMA; IMMUNOLOGY; MIDDLE AGED; PANCREAS TUMOR; RETROSPECTIVE STUDY; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0031594319     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.50     Document Type: Article

References (19)

1. Arakama Y, Aziga H, Kano M, Matsuo Y, Honda T and Mozita K (1985) Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers. Jn J Med 24: 121-130
2. Beastall GH, Cook B, Rustin GJS and Jennings J (1991) A review of the role of established tumour markers. Ann Clin Biochem 28: 5-18
3. Carmichael J, Fink U, Russell RCG, Spittle NF, Harris AL, Spiessi G and Blotter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105
4. De W Marsh R, Manyam V, Bewsher C and Youngblood M (1994) Circadian rhythm modulated 5-KUdR infusion with megace in the treatment of advanced pancreatic cancer. J Surg Oncol 57: 25-29
5. Evans TRJ, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG and Knight MJ (1996) A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1260-1264
6. Forsmark CE, Lambiase L and Vogel SB (1994) Diagnosis of pancreatic cancer and prediction of unresectability using the tumour-associated antigen CA19-9. Pancreas 9: 731-734
7. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O and Jolanko H (1986) Evaluation of CA19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53: 197-202
8. Kaplan ES and Meier P (1958) Nonpanometric estimation for incomplete observations. J Am Stat Assoc 53: 457-481
9. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D and Fulner P (1979) Colorectal carcinoma antigens detected by hydbridoma antibodies. Somat Cell Genet 5: 957-972
10. Lundin J, Roberts PJ, Kuusela P and Haglund C (1994) The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. Br J Cancer 69: 515-519
11. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H and Pugliese V (1988) CA19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 61: 2100-2108
12. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RCF (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882-885
13. Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J and Dowsett M and Harris AL (1993) Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH against goserelin plus hydrocortisone. Br J Cancer 67: 379-382
14. Schifeling DJ, Konski AA, Howard JM, Dobelbower RR Jr, Merick III HW and Skeel RT (1992) Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. Int J Pancreat 12, 239-243
15. Steinberg WM (1990) The clinical utility of the CA19-9 tumour associated antigen. Am J Gastroenterol 85: 350-355
16. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA and Cooper EH (1993) The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67: 1132-1135
17. Willett CG, Daly WJ and Warshaw AL (1996) CA19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172: 350-352
18. Wong A and Chan A (1995) The use of the tumour marker CA19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas. Eur J Cancer 31A: 2118-2119
19. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kumo N, Kurimoto K and Ohashi Y (1994) Prognostic values of preoperative and postoperative CEA and CA19-9 levels in pancreatic cancer. Pancreas 9: 735-740